DOCSLIB.ORG

Friends of Aids Research Alliance Stay Busy This Fall

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Friends of Aids Research Alliance Stay Busy This Fall WINTER 2007 | VOLUME 17, No. 2 AIDS RESEARCH SEARCHLIGHT ALLIANCE A NATIONAL LEADER IN FAST-TRACK AIDS RESEARCH In This Issue– 2 Message from the CEO 3 News and Views 5 HIV Viral Reservoirs: Barriers to a Cure 10 Viral Eradication: A Continuing Debate 12 Measuring The HIV Reservoir 14 Current Research and Clinical Trials at ARA 16 Can Animals Help? 17 Interview with Robert Siliciano, M.D., Ph.D. 18 Health Literacy: A Tool for People Living With HIV/AIDS 20 AIDS Research Alliance Welcomes New Members to the Board of Directors 21 Friends of AIDS Research Alliance Busy This Fall 25 An Evening with Nobel Laureate David Baltimore, M.D.M.D. 27 Combined Federal Campaign (CFC) THE CHALLENGE OF EMPTYINGEMPTYING THE HIV RESERVOIRRESERVOIR MESSAGE FROM THE CEO SEARCHLIGHT HIV VACCINE RESEARCH: A RISKY BUSINESS NEWS FROM AIDS RESEARCH ALLIANCE A NATIONAL LEADER IN FAST-TRACK AIDS RESEARCH AIDS RESEARCH ALLIANCE was one of the clinical sites for the Merck vaccine study that recently was halted by the Data Safety Monitoring Board (DSMB). In VISION collaboration with the National Institute of Allergy and Infectious Diseases AIDS Research Alliance (ARA) envisions a future in which HIV and (NIAID) and the HIV Vaccine Trials Network (HVTN), Merck conducted a its effects on health are eliminated, and new infections are prevented. MISSION STATEMENT phase IIb study of an aden- ovirus (common cold) based AIDS Research Alliance exists to develop a cure for HIV/AIDS, medical modalities to prevent new infections and better treatments vaccine designed to stimulate for those living with HIV. cell mediated immunity in RESEARCH BUSINESS MODEL healthy patients at higher risk The core areas of the AIDS Research Alliance non-profit research of contracting HIV. The clini- model include: 1. Independent clinical research, without regard to profit. cal trial of the vaccine was ter- 2. Clinical trials for innovative anti-HIV technologies and treat- minated prematurely when ments, and for vaccines, microbicides and other biomedical pre- vention research. data from the trial showed that 3. The development of treatments for HIV-related conditions. it was not effective in prevent- 4. Collaborations and strategic partnerships with other scientific organizations (including academic institutions, biotech and phar- ing HIV infection (compared to maceutical companies and governmental agencies). patients on placebo). Nor did it lower the viral load in patients who contracted EDITORIAL BOARD HIV during the course of the study. As one of the investigative sites for the Stephen J. Brown, MD Merck study, AIDS Research Alliance will continue to follow up with study vol- Carolyn H. Carlburg, JD Vincent M. Cummings unteers who participated in the trial. Marjan Hezareh, PhD Due in large part to our involvement in the clinical trial, AIDS Research Ava Lena Waldman, MHS Alliance was hopeful that the Merck vaccine candidate — one of about 30 HIV MANAGING EDITOR & PRODUCTION COORDINATOR vaccines currently in clinical trials — would demonstrate some degree of effec- Bernice Schacter, PhD tiveness of the underlying concept of cell mediated immunity. The fact that it did CONTRIBUTORS not is troubling because the majority of vaccine candidates currently in clinical Marc Borzelleca Herminio R. Reyes, PhD trials are based on the same concept. But the failure of the Merck vaccine should Stephen J. Brown, MD Peter Salveson be placed in perspective. One of the most respected scientists in the field, Dr. Marjan Hezareh, PhD Bernice Schacter, PhD Donald Herman Dave Schwep Anthony Fauci, the Director of NIAID, which is part of the National Institutes of Joe Jennings Lisa Vasey Health (NIH), framed the issue when he said, “Clearly this [the termination of ART DIRECTOR & ART PRODUCTION the Merck study] indicates the failure of a product. Whether or not it indicates Chris Davies / Shout, Inc. the failure of a concept, we don't know at this point.” PRE-PRESS & PRINTING Other leading scientists have weighed in on the issue. Dr. David Baltimore, Southwest Graphic Services Nobel Laureate for the shared discovery of reverse transcriptase, and former Searchlight is published for the medical research and HIV community president of the California Institute of Technology, recently said, “If you are by AIDS RESEARCH ALLIANCE, a California nonprofit corporation which is solely responsible for its content. Noncommercial reproduction is going to think about the most complicated issues in science, then you must be encouraged, provided the appropriate credit is given. prepared to be wrong. That doesn't ameliorate the awful disappointment at the CIRCULATION: 16,000 failure of the phase IIb Merck HIV vaccine trial…The greatest difficulty facing COPYRIGHT © 2007 AIDS RESEARCH ALLIANCE ALL RIGHTS RESERVED. vaccine researchers has been that none of their laboratory subjects (chimpanzees ISSN 1932-2526 and/or mice) are affected by HIV in precisely the same way as humans, making AIDS RESEARCH ALLIANCE it nearly impossible to tell how a vaccine will work in a human population.” 621-A North San Vicente Blvd. West Hollywood, CA 90069 This is not the first time that HIV vaccine research has suffered a major TAX I.D. 95-4264845 setback. In 1999, AIDS Research Alliance was a leading investigative site for the Telephone: (310) 358-2423 first Phase III preventative HIV vaccine candidate, VaxGen. In that case, the Fax: (310) 358-2431 underlying concept was that certain antibodies could be produced that would www.aidsresearch.org [email protected] confer immunity against HIV. When VaxGen failed, as AIDS Research Alliance @ Medical Director Stephen J. Brown has pointed out, “there was more informa- PRINTED ON RECYCLED PAPER continued on page 26 2 WINTER 2007 | SEARCHLIGHT NEWS AND VIEWS 4TH INTERNATIONAL AIDS SOCIETY IAS CONFERENCE ON HIV PATHOGENESIS, TREATMENT AND PREVENTION, SYDNEY, AUSTRALIA, JULY 22-25, 2007 HIV Antiretrovirals in Pipeline 2007 CLINICAL TRIAL NAME COMPANY PHASE TYPE PATIENTS Raltegravir Merck Co Approved Integrase inhibitor* Treatment naïve and (Twice daily) experienced with multi- drug resistant Elvitegravir (GS-9137) Gilead Phase III Integrase inhibitor Treatment naïve and (Once daily) experienced with multi- drug resistant Rilpivirine (TMC278) Tibotec & J&J Phase III NRTI** Treatment naïve Maraviroc Pfizer Approved CCR5 inhibitor *** Treatment naïve and experienced with multi- drug resistant Vicriviroc Schering Plough Phase II CCR5 inhibitor Treatment naïve and experienced Pro 140 Progenic Phase I CCR5 monoclonal Treatment naïve and antibody experienced Etravirine (TMC125) Tibotec and J&J Phase III NRTI Treatment experienced Bevirimat (PA-457) Panacos Stopped due to lack of Maturation inhibitors Not Determined correct formulation **** continued on next page SEARCHLIGHT | WINTER 2007 3 NEWS AND VIEWS continued from page 3 CLINICAL TRIAL NAME COMPANY PHASE TYPE PATIENTS TNX-355 Tanox Stopped due to dosing CD4 monoclonal anti- Not Determined issue body ***** BILR-355 Boehringer Ingelheim Phase I NNRTI ****** Not Determined Racivir Pharmasset Phase II NRTI Treatment-experienced Lamivudine-resistant virus Reverset Pharmasset Phase II NRTI Treatment-experi- enced, NRTI-resistant virus Amdoxovir RFS Pharma Phase II NRTI Treatment-experi- enced, NRTI-resistant virus Apricitabine (AVX754) Avexa Phase II NRTI Treatment-experi- enced, NRTI-resistant virus Elvucitabine Achillion Phase I NRTI Not Determined pharmaceuticals * The enzyme Integrase is required for productive infection of target cells and assembly of progeny virions. ** Nucleoside Reverse Transcriptase Inhibitor, blocks replication of the virus. *** CCR5 is a receptor for entrance of HIV into macrophages and some T cells. **** Maturation inhibitors prevent HIV from properly assembling and maturing, from forming a protective outer coat, or from emerging from human cells. ***** CD4 is a receptor that HIV uses to infect T cells. ****** Non-nucleoside Reverse Transcriptase inhibitor blocks replication of the virus. 4 WINTER 2007 | SEARCHLIGHT BASIC SCIENCE HIV VIRAL RESERVOIRS: BARRIERS TO A CURE Since 1996, remarkable advances in the Inhibitors, Protease Inhibitors and Entry/Fusion Inhibitors. treatment of human immunodeficiency Different combinations of three or more of these drugs, virus (HIV-1) have decreased progres- known as highly active antiretroviral therapy (HAART), sion to AIDS and the death rate among produce sustained suppression of viral replication in most HIV positive patients. Four classes of patients. Prolonged viral suppression raised hope for virus antiretroviral medications are currently available for the eradication. However, in 1997, three separate research treatment of HIV: Nucleoside Reverse Transcriptase groups, using sensitive co-culture techniques, were able to Inhibitors, Non-nucleoside Reverse Transcriptase recover replication competent HIV from purified CD4+ lymphocytes of patients on long-term HAART, despite BY MARJAN HEZAREH, Ph.D. prolonged undetectable virus in the plasma (<50 Dr. Hezareh has been AIDS Research Alliance’s Scientific copies/mL) [1-3]. The first estimation of the half life of Director since 2001. these reservoirs demonstrated that the reservoir decays SEARCHLIGHT | WINTER 2007 5 very slowly, with a long half-life of 44 months in patients needed. To this end, it is worth examining the nature of on HAART with sustained viral suppression for 7 years, viral reservoirs. rendering the eradication of HIV infection impossible with A latent reservoir is defined as a cell type or anatomical currently available
Load more

Recommended publications
  • 2008-2009Program Highlights
    AIDS FOUNDATION OF CHICAGO 2008-2009 PROGRAM HIGHLIGHTS The AIDS FOUNDATION OF CHICAGO is a force for change. We pursue a broad range of activities to end new infections, improve the lives of people with HIV, and strengthen government and community responses to the epidemic. Founded in 1985 by community activists and physicians, we fortify local, national, and international HIV-related activities. We specialize in efforts to: • Advocate with and for people affected by HIV/AIDS. • Fund and coordinate prevention, care, and advocacy projects. • Cultivate the capacity and expertise of individuals and organizations dedicated to ending HIV/AIDS. Together with our individual, government, and community partners, we reach tens of thousands of people in need each year and make our collective efforts better and stronger. We are a source of hope—a force for change. The AIDS Foundation of Chicago dedicates this report to the tens of thousands of Illinoisans affected by HIV/AIDS and the many dedicated volunteers and professionals who, through their daily activities, champion compassion and action in the wake of the HIV/AIDS crisis. A Force for Change Table of Contents: A message from the President/CEO, Board Chair and SPC Chair 7 Leadership and advocacy 8 Prevention and care 10 Preparing for the future 12 AFC 2.0: Our online presence 14 Special events 16 Financial summary 18 Corporate and Foundation Supporters 19 The Year Ahead 20 2009 Calendar of Events 21 Individual Donors 22 Board of Directors and Staff 27 Service Providers Council Executive Committee & Junior Board 28 AFC’s Service Providers Council 29 Thank You 30 A Look Back 31 Message from President/CEO, Board Chair, and SPC Chair Dear Friends: For nearly 25 years, the AIDS Foundation of Chicago (AFC) has been a source of hope and a force for change, working with key partners to reduce HIV transmission and improve the lives of people with and at risk for HIV through advocacy, funding, and collaboration.
    [Show full text]
  • Curriculum Vitae JANET KAZUKO YAMAMOTO, Ph.D
    Curriculum Vitae JANET KAZUKO YAMAMOTO, Ph.D. PRESENT POSITION: RESIDENCE: Professor 4309 SW 77th Street Department of Infectious Diseases & Pathology (ID&P) Gainesville, Florida 32608 College of Veterinary Medicine Phone: (352) 371-9219 University of Florida, PO Box 110880 Fax: (352) 337-0444 Gainesville, FL 32611-0880 Phone: (352) 294-4145 Fax: (352) 392-7128 E-mail: [email protected] EMPLOYMENT HISTORY: 1979-1981 James W. McLaughlin Predoctoral Fellow in Infection and Immunity, Department of Microbiology, The University of Texas Medical Branch, Galveston, (Supervisor, Dr. Howard M. Johnson). Characterized the xenogeneic responses observed during the interaction of human peripheral blood lymphocytes and mouse spleen cells. Identified human natural killer cell activity towards mouse immunocytes, nonspecific soluble helper activity of human T cells towards mouse antibody response, and suppressor cell activity of mitogen and alloantigen-stimulated human T cells towards mouse antibody response. 1981-1982 NIH PHS Postdoctoral Fellow in the laboratory of Drs. Richard W. Dutton and Susan L. Swain, Department of Biology, University of California, San Diego. Evaluated the role of lymphokines (interleukin-2 and interferon-γ) in the developing primary and secondary antibody responses in mice. 1982-1983 Research Associate Scientist in the laboratory of Drs. Robert A. Good and N.K. Day, Oklahoma Medical Research Foundation, Oklahoma City. Analyzed the immunological status of feline leukemia virus (FeLV)-positive cats that were undergoing ex vivo immunoabsorption therapy with protein A column. 1983-1985 Postgraduate Researcher IV in the Department of Medicine, School of Veterinary Medicine, University of California, Davis. Produced and purified feline interferons (α, ß, and γ) and characterized their effect against FeLV.
    [Show full text]
  • Message from the Dean
    Developing the Next Generation of Healthcare Leaders ANNUAL REPORT 2009-10 Message from the Dean Solid Foundation Prepares Strong Future As I look back on our accomplishments during the 2009-2010 academic year, I am reminded of one of our greatest accomplishments to date – the Groundbreaking Ceremony for John and Editha Kapoor Hall. This event represents the beginning of our future as well as the focus of all we currently strive to achieve and enhance. Kapoor Hall will allow us to attain our curricular objectives, advance our research, expand collegial interactions and assist all members of the school in reaching their goals. The September 2009 Groundbreaking Ceremony laid the foundation for our occupancy of the building in the Summer of 2012. Our PharmD students were very active in pharmacy and healthcare policy objectives. Legislatively, SPAWNY organized a very successful Pharmacy Legislative Advocacy Day where local legislators visited the school and spoke with students about state health care policy and budget. APhA-ASP tackled legislative issues with the creation of a video showing how pharmacy impacts heath care reform at the local and regional levels. This was submitted to APhA as well as state and federal congressional offices. Nationally, the UB Team again took top honors with fourth place recognition at the AACP’s Pruitt-Schutte Business Plan Competition. On campus, our students represented the school well by their invited participation at the UB Celebration of Academic Excellence where PharmD and pharmaceutical sciences students showcased their research work via poster presentations. The continued high caliber work of our faculty continues to be recognized.
    [Show full text]
  • Minocycline Treatment for HIV-Associated Cognitive Impairment Results from a Randomized Trial
    Minocycline treatment for HIV-associated cognitive impairment Results from a randomized trial N. Sacktor, MD ABSTRACT S. Miyahara, PhD Objective: We conducted a study of minocycline to assess its safety, tolerability, and efficacy for L. Deng, MS the treatment of HIV-associated cognitive impairment. S. Evans, PhD Methods: HIV-1-infected individuals with progressive neurocognitive decline were enrolled in a G. Schifitto, MD double-blind, placebo-controlled study of minocycline. Participants were randomized to receive mino- B.A. Cohen, MD cycline 100 mg or matching placebo orally every 12 hours. The primary efficacy measure was change R. Paul, PhD in a neuropsychological test composite z score (NPZ-8) from baseline to week 24. Measures of safety K. Robertson, PhD included the frequency of adverse events and changes over time in laboratory tests. After 50% of B. Jarocki, BS participants completed the double-blind phase, an interim analysis of futility for the primary outcome mea- K. Scarsi, PharmD sure was performed, and our Data and Safety Monitoring Board recommended early study termination. R.W. Coombs, MD, Results: A total of 107 HIV-1-infected individuals with cognitive impairment were enrolled. The PhD minocycline group did not show improvement in the primary outcome measure (NPZ-8) (mean M.C. Zink, DVM, PhD 24-week change ϭ 0.12) compared to placebo (mean 24-week change ϭ 0.17) (95% confidence A. Nath, MD interval ϭ [Ϫ0.26, 0.39], p ϭ 0.70). There were few severe adverse events or laboratory abnor- E. Smith, MD malities in either treatment group. R.J.
    [Show full text]
  • Media Experts List
    Media Experts List The American Statistical Association (ASA) maintains a database of members with expertise in fields of statistical application who have volunteered to serve as sources of information for the media. The individuals on the list speak as experts in their fields, not as ASA spokespersons. While we have provided a list of topics in an effort to help you find individuals easily, please note that these members are not subject experts, but have expertise in the statistical aspects of the topics listed. Many of the individuals on the list have experience working with media and can be relied on as resources for quotes, interviews, and background information. Please note that the topic categories are fairly broad (and evolving), and we would recommend that you consult the expert bios in this document to determine if an individual meets your requirements. The list continues to grow, and we will issue updates as they become available. If you have need of a resource in an area not reflected here, we will be happy to try to locate someone for you. Please contact the ASA’s public relations manager at (703) 684-1221. ASA Media Experts List by Topic Actuarial Science Christopher Schmid Edward Melnick Nozer Singpurwalla Richard Smith Affirmative Action / Discrimination Hal Stern Arlene Ash Peter Thall Joseph L. Gastwirth David Marker Bioinformatics Marty Wells Terence Speed Aging Biological / Ecological Applications Charles Hall Bahman Shafii Mack Shelley Biometrics AIDS Bahman Shafii Jimmy Efird Biopharm / Clinical trials Air Pollutants
    [Show full text]
  • 06-308 Nm Aids
    2006Report HIVM EDICINES IN/DAIDSEVELOPMENT FOR PRESENTED BY AMERICA’ S PHARMACEUTICAL COMPANIES Researchers Are Testing 77 Medicines and Vaccines For HIV and Opportunistic Infections IV/AIDS is one of the world’s most devastating M EDICINES IN D EVELOPMENT FOR AIDS* diseases. To help fight it, biopharmaceutical Hresearchers are testing 77 medicines for HIV/AIDS Anticancers 4 and related conditions and intensifying their work toward Antifungals 1 the development of vaccines. The medicines now in the Anti-Infectives pipeline will add to the 88 already approved since the 2 AIDS virus was first identified more than 20 years ago. Antivirals 35 Vaccine research is crucial to the fight against AIDS. Gene Therapy 2 “A safe and effective HIV vaccine is critical to the control Immunomodulators 7 of HIV globally,” says Dr. Anthony Fauci, Director of the Vaccines 19 National Institute of Allergy and Infectious Diseases. Other Currently, 19 vaccines are in development. 9 According to the Joint United Nations Programme on *Some medicines are listed in more than one category. HIV/AIDS, over the last quarter century, nearly 65 million people were infected with HIV, and an estimated • A vaccine combines DNA snippets from the AIDS 25 million have died of AIDS-related illnesses. As many virus with a protein that boosts immune response. as 1.2 million U.S. residents are estimated to be living The vaccine may prevent infection, limit the damage with HIV infection. Today it is estimated that close to the virus causes, or both. 40 million people worldwide live with HIV—yet the vast • An antisense gene therapy uses two novel technolo- majority are unaware of their status.
    [Show full text]
  • Nurses Research Publication AIDS UPDATE
    Nurses Research Publication Presents: AIDS UPDATE 2001 Edition Nurses Research Publication, P.O. Box 480, Hayward, California, 94543-0480 Copyright © 2001, 15th ed., Nurses Research Publication (510) 888-9070 ALL RIGHTS RESERVED. No part of this material may be reprinted, reproduced, transmitted, stored in a retrieval system, or otherwise utilized, in any form or by any means electronic or mechanical, including photocopying or recording, now existing or hereinafter invented, nor may any part of this course be used for teaching without the written permission from the publisher and author. For low-cost copies, contact Nurses Research Publication. License Renewal: In California, the RN and LVN State Board requires you to fill out a form with continuing education information in order to renew your license. The Board does not normally require the completion certificate, just the information printed on your certificate. Do not send the board certificates unless they specifically ask for one. If you should need your certificate rushed, we can FAX a copy for $5. The original certificate will be mailed for free. COURSE OUTLINE/TABLE OF CONTENTS CHAPTER I THE HISTORY AND DISCOVERY OF THE HIV VIRUS Page 5 A. The First Reported Cases B. Definition of the Disease C. The HIV Retrovirus D. Transmission of the HIV Virus CHAPTER II HIV AND AIDS MORBIDITY AND MORTALITY STATISTICS Page 13 The Incidence of AIDS Incidence Tables of HIV infection and AIDS CHAPTER III LABORATORY TESTING FOR THE HIV VIRUS Page 17 Screening Tests for HIV infection Immunological
    [Show full text]
  • HIV, HCV, TB: 2012 Pipeline Report, TAG and I-Base
    ABOUT HIV i-BASE HIV i-Base is a London-based HIV treatment activist organization. HIV i-Base works in the United Kingdom and internationally to ensure that people living with HIV are actively engaged in their own treatment and medical care and are included in policy discussions about HIV treatment recommendations and access. www.i-base.info ABOUT TAG The Treatment Action Group (TAG) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. www.treatmentactiongroup.org 2012 PIPELINE REPORT HIV, HEPATITIS C VIRUS (HCV), AND TUBERCULOSIS (TB) DRUGS, DIAGNOSTICS, VACCINES, AND PREVENTIVE TECHNOLOGIES IN DEVELOPMENT By Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan Edited by Andrea Benzacar JULY 2012 i-BASE/TREATMENT AcTION GROUP AUTHORS Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan. EDITOR Andrea Benzacar DESIGNER Lei Chou ACKNOWLEDGMENTS Thanks to the TAG staff, board, and donors for supporting the production of the 2012 Pipeline Report. i-Base thanks the Monument Trust and UNITAID for support for this work. Polly Clayden thanks Shaffiq Essajee, Di Gibb, Andrew Hill, David Ripin, and Marco Vitoria. Richard Jefferys thanks Jennifer Woolley from Aeras and Erna Balk from the TuBerculosis
    [Show full text]
  • Small-Cap Research [email protected]
    January 22, 2013 Grant Zeng, CFA 312-265-9466 Small-Cap Research [email protected] scr.zacks.com 111 North Canal Street, Chicago, IL 60606 GeoVax Labs Inc. (GOVX-OTC) GOVX: Unique preventive and therapeutic HIV/AIDS vaccine development technology OUTLOOK with candidates in efficacy studies-- Outperform GOVX is a unique developer for both preventive and therapeutic HIV vaccines. The Company s preventive HIV vaccine is among the only 5 candidates out of more than 90 vaccines entering HVTN Phase I testing Current Recommendation Outperform chosen to progress to Phase II clinical trials. Prior Recommendation N/A Date of Last Change 01/15/2013 Both HIV/AIDS vaccine and treatment markets are huge and GOVX has the potential to be a key player in the two markets. Management will continue to Current Price (01/18/13) $0.77 create shareholder value by generating new clinical $1.50 Twelve- Month Target Price data, bringing in government support and partnership. We believe valuation is attractive with the potential for SUMMARY DATA substantial returns. 52-Week High $1.20 Risk Level Above Avg., 52-Week Low $0.63 Type of Stock Small-Growth One-Year Return (%) -12.66 Industry Med-Biomed/Gene Beta 1.32 Zacks Rank in Industry N/A Average Daily Volume (sh) 23,027 ZACKS ESTIMATES Shares Outstanding (mil) 20.5 Market Capitalization ($mil) $15 Revenue (in millions of $) Short Interest Ratio (days) N/A Q1 Q2 Q3 Q4 Year Institutional Ownership (%) 36.8 Insider Ownership (%) 7 (Mar) (Jun) (Sep) (Dec) (Dec) 2011 0.89 A 1.75 A 1.30 A 0.96 A 4.90 A Annual Cash Dividend $0.00 2012 0.86 A 0.71 A 0.64 A 0.70 E 2.90 E Dividend Yield (%) 0.00 2013 0.75 E 0.75 E 0.75 E 0.75 E 3.00 E 2014 2.50 E 5-Yr.
    [Show full text]
  • 2011 Pipeline Report Second Edition
    i-base HIV, HEPATITIS C VIRUS (HCV), AND TUBERCULOSIS DRUGS, DIAGNOSTICS, VAcciNES, AND PREVENTIVE TECHNOLOGIES IN DEVELOPMENT 2011 Pipeline Report Second Edition SEPTEMBER 2011 i-BASE / TREATMENT ACTION GROUP POLLY CLAYDEN, SIMON COLLINS, MARK HARRINGTON, RICHARD JEFFERYS, TRACY SWAN, JAVID SYED, AND CLAIRE WINGFIELD WITH A CONTRIBUTION BY JONATHAN BERGER ABOUT HIV i-BASE HIV i-Base is a London-based HIV treatment activist organization. HIV i-Base works in the United Kingdom and internationally to ensure that people living with HIV are actively engaged in their own treatment and medical care and are included in policy discussions about HIV treatment recommendations and access. HIV i-Base 4th Floor 57a Great Suffolk Street London SE1 0BB Tel +44 (0) 20.7407.8488 Fax +44 (0) 20.7407.8489 [email protected] www.i-Base.info ABOUT TAG The Treatment Action Group (TAG) is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS. TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information. Treatment Action Group 261 Fifth Avenue Suite 2110 New York, NY 10016 Tel 212.253.7922 Fax 212.253.7923 [email protected] www.treatmentactiongroup.org SECOND EDITION ISBN 978-0-9819863-9-5 THIS REPORT IS DEDICATED TO HIV and Human Rights Activist Dr. Robert Carr (d. 2011) and Ugandan LGBT Activist David Kato Kisule (1964–2011) Table of Contents Introduction and Executive Summary 1 The Antiretroviral Pipeline 17 The Pediatric Antiretroviral Pipeline 38 HIV
    [Show full text]
  • Curriculum Vitae W. David Hardy, MD
    Curriculum Vitae W. David Hardy, M.D. PERSONAL HISTORY: Office Address: 6123 Maryland Drive Los Angeles, California 90048 Office Phone: (310) 709-3505 Email: [email protected] Mobile Phone: (310) 709-3505 Place of Birth: Dallas, Texas Citizenship: United States of America Partner: Barry Goldblatt EDUCATION & TRAINING: 1974-1977 University of Texas at Austin, Texas; (Zoology/Classics) Summa Cum Laude 1977-1981 Baylor College of Medicine, Houston, Texas; Doctor of Medicine with Honors 1981-1982 Internship in Internal Medicine, Department of Medicine, Baylor College of Medicine Affiliated Hospitals, Houston, Texas 1982-1984 Residency in Internal Medicine, Department of Medicine, Harbor-UCLA Medical Center, Torrance, California 1984-1986 Clinical Fellowship in Infectious Diseases and Clinical Immunology (Mentors- Michael S. Gottlieb, MD/Lowell Young, MD), Department of Medicine, University of California - Los Angeles School of Medicine, Los Angeles, CA 1984-1986 Clinical Research Fellowship (Mentor-Michael S. Gottlieb, MD), UCLA AIDS Center, Department of Medicine, University of California – Los Angeles School of Medicine, Los Angeles, California 1998-2002 Laboratory Research Fellowship, Laboratory of Irvin S. Y. Chen, Ph.D., Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, UCLA, Los Angeles, CA LICENSURE: State of Texas: #F-9536, (inactive) State of California: #C-40623, (active) District of Columbia: #MD043801, (active) BOARD CERTIFICATION: 1984 Diplomat, Internal Medicine, American Board
    [Show full text]
  • INSIDER Quark
    DEDICATED TO THE PEOPLE WHO MAKE THE INSTITUTE’S ACHIEVEMENTS POSSIBLE Volume 1, Issue 1 July 2003 Sherri Lewis, a longterm survivor The UCLA AIDS Institute at the United Nations: of HIV infection, has a relationship Exporting our expertise around the globe page 6 Teaching homeless teenagers how to keep from with her UCLA physician that spans contracting HIV page 12 two generations and two genders page 4 “We lit the match that got the fire started”: Everyday heroes launch a grass-roots effort to fund the Institute's vaccine research page 14 A Los Angeles legend leaves a legacy for vaccine research page 14 A Message from the Director Introducing Insider A new publication from the UCLA AIDS Institute—dedicated to the people who make our achievements possible ast year the UCLA AIDS Institute competed— successfully, I am happy to report—for renewal Lof the multi-year, multi-million-dollar federal grant that supports much of the long-range work being done by the hundreds of researchers a≈liated with our Institute. These projects range from programs to H develop promising HIV vaccines to programs that G U H recruit HIV-negative wet-nurses to breast-feed babies c M M I born to HIV-positive mothers, so that those babies do J not contract the virus before they can be weaned. The renewal application that the AIDS Institute “In the beginning, when an idea is little submitted to the National Institutes of Health provided an abbreviated description of every project being undertaken more than a gleam in a researcher’s eye, by our researchers.
    [Show full text]